Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTS maintains a portfolio focused on the Biotechnology & Pharmaceuticals technology area. The organization currently faces 2 pending office actions distributed across 2 distinct examiners. This distribution indicates that each pending action is handled by a different examiner, which can often lead to varied prosecution timelines depending on individual examiner speeds.
Prosecution activity is concentrated within 1 distinct art unit. Examiner GODDARD, LAURA B is identified as the busiest examiner for this portfolio, currently handling 1 busiest examiner pending office action. This single action represents one of the 2 pending office actions currently active for the company. Having all activity within the Biotechnology & Pharmaceuticals area suggests a highly specialized technological focus, even as the work is split between 2 distinct examiners. This concentration allows for a deeper understanding of the specific art unit's standards and preferences during the examination process.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GODDARD, LAURA B | 1 | 50.9% | +13.5% |
| LEE, JAE W | 1 | 65.8% | +38.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17750061 | CHEMICALLY INDUCIBLE POLYPEPTIDE POLYMERIZATION | LEE, JAE W | 14d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17750061 | CHEMICALLY INDUCIBLE POLYPEPTIDE POLYMERIZATION | LEE, JAE W | 14d |
| 18688693 | ANTI-CECAM6 ANTIBODIES WITH REDUCED SIDE-EFFECTS | GODDARD, LAURA B | — |
| Art Unit | Apps |
|---|---|
| 1656 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18688693 | ANTI-CECAM6 ANTIBODIES WITH REDUCED SIDE-EFFECTS | GODDARD, LAURA B | — | §103§112DP | Non-Final OA | — | Pending | Mar 01, 2024 |
| 17750061 | CHEMICALLY INDUCIBLE POLYPEPTIDE POLYMERIZATION | LEE, JAE W | 1656 | §102§112 | Non-Final OA | 14d | Pending | May 20, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial